Teva Names Lundbeck's Schultz as CEO to Revive Drugmaker


Teva Pharmaceutical Industries Ltd. named H. Lundbeck A/S's Kaare Schultz as its new chief executive officer, turning to an industry veteran to try to revive sales and reduce debt at the world's largest maker of generic drugs. Schultz, 56, will move to Israel and be based at Teva's headquarters in Petach Tikva, the company said in a statement Monday.



from Biotech News